Related references
Note: Only part of the references are listed.Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Marie Jose Kersten et al.
HAEMATOLOGICA (2021)
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Reid W. Merryman et al.
BLOOD ADVANCES (2021)
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Ranjana H. Advani et al.
BLOOD (2021)
How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents
Julia Driessen et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2021)
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
Alison J. Moskowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy
Nicole A. Carreau et al.
ONCOLOGIST (2020)
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience
Beatrice Casadei et al.
HEMATOLOGICAL ONCOLOGY (2020)
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma
Beatrice Casadei et al.
CANCER MEDICINE (2020)
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
Khadega A. Abuelgasim et al.
BONE MARROW TRANSPLANTATION (2019)
Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease
Ann S. LaCasce
HEMATOLOGICAL ONCOLOGY (2019)
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Robert Chen et al.
BLOOD (2019)
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
A. Broccoli et al.
BLOOD CANCER JOURNAL (2019)
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers
Cedric Rossi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Alex F. Herrera et al.
BLOOD (2018)
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P. E. Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
Alison J. Moskowitz et al.
BLOOD (2017)
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
A. Younes et al.
ANNALS OF ONCOLOGY (2017)
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
Bruce D. Cheson et al.
BLOOD (2016)
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
Sally F. Barrington et al.
BLOOD (2016)
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma
Ann S. LaCasce et al.
BLOOD (2015)
Immunological off-target effects of standard treatments in gastrointestinal cancers
A. G. Duffy et al.
ANNALS OF ONCOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
N. L. Bartlett et al.
ANNALS OF ONCOLOGY (2007)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial
N Schmitz et al.
LANCET (2002)
Share Paper
